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ABSTRACT
Background and Objectives: Dysfunction of arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs) contributes 
significantly to morbidity and hospitalization in the dialysis population. We evaluated the primary patency of AVFs following 
percutaneous transluminal angioplasty (PTA) in haemodialysis patients. Subjects and Methods: We performed 231 inter-
ventions in 118 patients with a mean age of 62.1±12.9 years. We performed 122 interventions in 53 AVG patients (44.9%), and 
109 interventions in 65 AVF patients (55.1%). If there was thrombosis of the vascular access, urokinase was administered and/ 
or thrombus aspiration was performed. The stent was inserted when balloon dilatation did not expand sufficiently or elastic 
recoil occurred. Results: For the 118 patients, the median patency time was 10.45±10.29 months at 92 months of follow-up. 
The primary patencies for stenotic AVFs at 6, 12, 24, 36, 48, and 60 months were 63.4%, 41.4%, 17.0%, 9.7%, 7.3%, and 2.4%, 
respectively. The primary patencies for AVGs at 6, 12, 24, and 36 months were 36.9%, 19.5%, 10.8%, 2.1%, respectively, and 
were obtained by means of the Kaplan-Meier analysis (log rank=6.42, p<0.05). The median patency time was 11.0 months 
and 4.45 months in the non-thrombus and thrombus groups, respectively. The complication rate was 1.73% (4/231); two cases 
of pseudoaneurysms and two cases of extravasation were detected. All therapy failures (5/231) occurred in thrombotic le-
sions of AVGs and were treated surgically. Conclusion: PTA is an efficacious method for the correction of stenosis of AVFs 
for hemodialysis, thus prolonging the patency of the fistulas. (Korean Circ J 2011;41:512-517)
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Introduction
Hemodialysis can be performed via central venous cathe-
ters (internal jugular, subclavian and femoral vein) or via a per-
manent arteriovenous access. Long-term patency of central 
catheters is low, because they are prone to infection and th-
rombosis.
1) The stenosis and subsequent thrombosis of arte-
riovenous fistulas (AVFs) may lead to a loss of vascular access 
sites. Dysfunction of AVFs and arteriovenous grafts (AVGs) 
occurs frequently in haemodialysis patients and contributes 
significantly to morbidity and hospitalization in the dialysis 
population.
2)
In recent years, percutaneous interventional techniques 
have been tried and established as a viable alternative means 
in the management of fistula dysfunction. In recent years, se-
veral studies
3-9) have demonstrated that angioplasty is effica-
cious with some advantages compared to the conventional 
surgical treatment such as a shorter time needed to perform 
the procedure and shorter hospitalization, less discomfort 
for the patient, and lower infection rates. Additionally, it en-
ables dialysis immediately after the procedure without the 
necessity of using a central venous catheter. 
In Korea, however, the data regarding the results of percu-
taneous transluminal angioplasty (PTA) in dysfunctional fi-
stulas is limited. In this study, we evaluated the primary pa-
tency of AVFs after PTA in haemodialysis patients.Woo Shin Kim, et al.   513
Subjects and Methods
We performed 231 interventions in 118 patients on hemo-
dialysis for chronic renal failure. There were 65 men and 53 
women with a mean age of 62.1±12.9 years (range, 28-86 ye-
ars). Patients with malfunctioning arteriovenous access who 
presented at the Combined Internal Medicine/Intervention-
al Radiology Service at Mokdong Hospital, School of Medi-
cine of Ewha Womans University were followed between Jan-
uary 2002 and September 2009. The drop-out rate was 23.7% 
(28 patients) (Table 1). 
A 5 to 7 Fr introducer sheath was inserted anterogradely 
or retrogradely according to the site of stenosis and angiogra-
phy was performed. Diagnostic angiography was performed 
through the sheath. A hydrophilic-coated, steerable, 0.035-
inch Terumo guidewire (Terumo Corp., Tokyo, Japan) was 
passed. A balloon catheter was then passed over the guidewire 
and advanced to the most central lesion. According to the size 
of the veins, 4-, 6-, 8-, 10-, and 12-mm balloons were used. Bal-
loon size was determined based on the findings on fistulog-
raphy or the known graft diameter (Fig. 1). A pressure of 10 
atm was routinely utilized. If this was not effective in breaking 
the lesion, pressures of 15 and 20 atm were sequentially appli-
ed. The balloon was allowed to remain inflated for 1-2 min-
utes with each inflation. Multiple inflations were used for re-
sistant lesions. The choice of the appropriate percutaneous ap-
proach depends on the size and location of the thrombus de-
tected by angiography. A short segment thrombosis can be 
simply treated with balloon angioplasty alone; however, an 
extensive thrombosis requires the combination of mechani-
cal devices and/or thrombolytic agents with consecutive bal-
loon angioplasty. Delivery of 100,000 to 400,000 U of uroki-
nase directly into the thrombus was performed in our patients 
with use of the pre-existing catheter. For thrombosed fistulas, 
a manual catheter-based thromboaspiration and/or mecha-
nical thrombectomy with an Arrow-Trerotola percutaneous 
thrombolytic device (ARROW International Inc., Reading, 
PA, USA) was performed (Fig. 2). Despite the complete ex-
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Fig. 1. A severe stenotic lesion. A: stenosis in the anastomotic fistulae between the brachial artery and basilic vein. B: a waist in the 14 mm   
length balloon is seen. C: percutaneous transluminal angioplasty with 16 mm length balloon. D: post-angioplasty injection shows near reso-
lution of the stenosis.
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pansion of the balloon (without a waist) of sufficient diame-
ter, the dilated vessel wall may collapse immediately after re-
moval of the balloon. This elastic recoil was treated with 
stent implantation in two cases. Also, the stent was inserted 
when the balloon dilatation did not expand sufficiently in two 
cases. A post-procedural fistulography was performed to as-
sess and document the results of the therapy. Following the 
removal of the vascular sheath, hemostasis was achieved by 
manual compression. 
Primary patency was defined as patency during the inter-
val between primary intervention and repeated radiologic 
intervention because of dysfunction in permanent hemodialy-
sis vascular access. Secondary patency was defined as patency 
during the interval between primary intervention and the 
time when the fistula was surgically declotted, revised, or ab-
andoned; the time when the patient received a renal transpl-
ant; death, or the time when the patient was lost to follow-up.
Follow-up of this study ended on September 1, 2009.
Statistical analysis
Statistical analyses were performed using Statistical Pack-
age for the Social Sciences (SPSS) 12.0 statistical software for 
Windows (SPSS Inc, Chicago, IL, USA). Discrete variables are 
presented as percentages, and continuous variables, as mean± 
SD. Standard deviation and frequency analysis was used to 
evaluate the general characteristics of the patients. Paired t-test 
and chi-square test was used to determine the significance of 
the difference between continuous variables. Primary patency 
rates were calculated according to the Kaplan-Meier life-table 
analysis. P less than 0.05 was considered statistically significant. 
Results
General characteristics of patients with 
malfunctioning arteriovenous access
The average number of times the intervention was perform-
ed was 1.96 (range, 1-10). The procedure time ranged from 20 
minutes to 190 minutes. The mean time from creating the 
AVF to AVF dysfunction was 13.14±11.58 months. 
The general characteristics of the patients are shown in Ta-
ble 1. The number of patients with diabetes was 71 (60.2%) 
and without diabetes was 47 (39.8%). Thrombi were found in 
57 patients (48.3%). The number of patients with AVF was 
65 (55.1%), and with AVG was 53 (44.9%). We performed 122 
interventions in 53 patients with AVGs, and 109 interventions 
in 65 patients with AVFs. In comparison with the AVF group, 
the AVG group had a higher rate of thrombosis (23.1% vs. 
79.2%, p<0.001).
The patency rate after percutaneous transluminal 
angioplasty
For the 118 patients, the median patency time was 10.45± 
10.29 months at 92 months of follow-up. The primary pa-
tencies for stenotic AVFs at 6, 12, 24, 36, 48, and 60 months 
were 63.4%, 41.4%, 17.0%, 9.7%, 7.3%, and 2.4%, respectively. 
The primary patencies for AVGs at 6, 12, 24, and 36 months 
were 36.9%, 19.5%, 10.8%, 2.1%, respectively, and were ob-
tained by means of the Kaplan-Meier analysis. The results of 
log-rank test for the Kaplan-Meier analysis of these life-ta-
bles revealed significant differences (log-rank=6.42, p<0.05) 
(Fig. 3). The secondary patency rate was 48.3% at 6 months.
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Fig. 2. Thrombosed fistula. A: fistulogram shows a total occlusion involving a thrombus at the arterial anastomosis of a brachial-axillary dial-
ysis graft. B: angiogram shows the balloon inflated at the diseased segment. C: angiogram after ballooning shows insufficient dilatation and 
residual clots. D: radiograph shows that an Arrow-Trerotola percutaneous thrombolytic device is used at the lesions of clots. E: final angiog-
raphy shows no residual clots and confirmed an excellent result.Woo Shin Kim, et al.   515
The duration of patency according to the type 
of endovascular therapy
The endovascular techniques used in the interventions and 
corresponding duration of patency are shown in Table 2. 
When we compared the duration of patency according to the 
type of intervention, no statistically significant difference was 
found (p=0.154).
The comparison of primary patency between the 
non-thrombus and thrombus groups
The median patency time after PTA was 11.0 months and 
4.45 months in the non-thrombus and thrombus groups, re-
spectively. Primary patency rates in the non-thrombus group 
at 6, 12, 24, 36, 48, 60 months were 68.2%, 46.3%, 19.5%, 
9.7%, 7.3%, and 2.4%, respectively. Primary patency rates in 
the thrombus group at 6, 12, 24, 36 months were 32.6%, 15.2%, 
8.7%, 2.1% respectively, and were obtained by means of the 
Kaplan-Meier analysis. Kaplan-Meier analysis of these life-ta-
bles revealed significant differences (log-rank=11.95, p<0.001) 
(Fig. 4). 
The comparison of primary patency between 
diabetics and nondiabetics
When we compared the duration of patency between the 
diabetic and nondiabetic patients, the duration of patency was 
9.80 months in the diabetic group and 11.42 months in the 
nondiabetic group, thereby showing a higher duration of pat-
ency in the nondiabetic group (p=0.609). The primary pa-
tency rates in the diabetic group at 6, 12, 24, and 36 months 
were 48%, 32.6%, 11.5%, and 5.7%, respectively, and 51.4%, 
25.7%, 17.1%, and 5.7%, respectively, in the nondiabetic gr-
oup, and were obtained by means of the Kaplan-Meier analy-
sis. There were no statistically significant differences between 
the groups in the patency rates (log-rank=0.35, p>0.05). 
The comparison of patency rate according to 
urokinase infusion
No significant difference was detected in the patency rate 
between patients with and without urokinase infusion (log-
rank=0.00, p>0.05).
Fig. 3. Primary patency rates of AVFs and AVGs (p<0.05). AVF: ar-
teriovenous fistula, AVG: arteriovenous graft.
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Table 1. Baseline characteristics of the study patients
Parameters Value 
Total number of patients 118
Men (%) 65 (55.1) 
Women (%) 53 (44.9) 
Age (years) 62.1±12.9
Diabetes (%) 71 (60.2)
Arteriovenous fistula (%) 65 (55.1)
Arteriovenous graft (%) 53 (44.9)
Thrombosis  (%) 57 (48.3)
Thrombosis in arteriovenous fistula (%) 15 (23.1)
Thrombosis in arteriovenous graft (%) 42 (79.2)
Duration from operation to dysfunction 
  of arteriovenous fistulas (months)
13.14±11.58
Table 2. Differences in the duration of patency according to the type of intervention
Type of intervention  Number Mean (months) Standard deviation F (p)
Balloon angioplasty 77 12.40 15.20
1.717 (0.154)
Pharmacologic thrombolysis 12 3.52 3.86
Mechanical thrombolysis 14 6.33 14.40
Pharmacomechanical thrombolysis 11 7.83 10.72
Endovascular stent placement 4 20.63 19.11
Total 118 10.45 14.29
Fig. 4. Primary patency rate in the thrombus group and non-th-
rombus group (p<0.001).
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Complications and failures
The complication rate was 1.73% (4/231; 2 cases of pseu-
doaneurysms and 2 cases of extravasation). Initial therapy 
failures were seen in all the AVG thrombus lesions. The failure 
rate was 2.16% (5/231; >30% residual stenosis after angio-
plasty). Either new AVF formation or surgical thrombecto-
my was performed in the cases of failed intervention.
A re-stenosis can be treated radiologically, with or without 
a stent, or surgically, depending upon the individual situation 
and the potential invasiveness of the surgical treatment. 
Discussion
The AVF is regarded as the vascular access of choice for he-
modialysis because of its superior patency and lower complic-
ation rates. Vascular access complications are one of the main 
causes associated with an increase in morbidity and mortali-
ty in stage 5 chronic kidney disease patients.
10) Stenosis is con-
sidered the major cause of AVF dysfunction. The pathogene-
sis of venous stenosis is not fully understood. The pathophy-
siology underlying the occurrence of stenosis is complex. It 
includes cellular proliferation, microvessel formation, and cy-
tokine expression by smooth muscle cells, endothelial cells, 
and macrophages.
11) The cytokines result in further activation 
and proliferation of these cell types, ending in venous neo-
intimal hyperplasia.
11)
In the past, surgical treatment performing correction of the 
stenotic lesion using a bypass or a patch was the only option. 
Comparison of outcomes of surgical versus percutanuous 
repair of a dysfunctional fistula is confusing. The cumulative 
patency rates for AVFs have not been shown to be superior 
with the use of either method. The success rate of PTA varies 
in different centres. Surgical repair has been reported to achi-
eve cumulative 1-year primary patency rate of approximately 
55%.
12)13) 
For thrombosed AVFs, a poor patency rate was initially re-
ported; Vorwerk et al.
14) reported a primary patency of 50% 
at 6 months. Overbosch et al.
15) reported the median prima-
ry patency being 14 weeks. Later, Turmel-Rodrigues et al.
16) 
reported better results, with primary and secondary patency 
rates (including initial technical failure) at 6 and 12 months 
of 74% and 81%, and 60% and 81%, respectively. In 2000, 
Turmel-Rodrigues et al.
17) reported primary and secondary 
1-year patency rates of 49% and 81%, respectively for failure 
and thrombosed forearm fistulas. In 2001, Manninen et al.
18) 
reported primary patency rates of 58% at 6 months and 44% 
at 1 year. In 2003, Kim et al.
19) reported primary patency rates 
of 58.7±5.2% at 6 months, 43.0±6.0% at 1 year and 18.1± 
6.0% at 2 years. Secondary patency rate of 40.0±8.1% at 2 
years was reported. In 2008, in a study by Miquelin et al,
7) a 
total of 22 angioplasties were performed in 20 fistulae of 19 
patients. Primary patency was 82.4% over three months; 
81.2% over six months; 54.5% over 9 months and 50% over 
1 year. In our study, the primary patencies were compared on 
the basis of thrombosis, diabetic status, endovascular techni-
cal methods, AVF and AVG. Lower primary patency rates 
were seen in AVGs and thrombus groups compared to other 
studies.
Since 1988, multiple reports have described the use of me-
tallic stents to primarily treat central venous stenoses. Early re-
ports were very optimistic. Landwehr et al.
20) treated 7 pa-
tients with central vein stenoses with Palmaz stents. They de-
scribed a 100% technical success rate, but the follow-up pe-
riod was limited. More recent reports have included longer 
follow-up and the findings have been more modest. Oderich 
et al.
21) presented 40 central venous obstructions that were tr-
eated with 50 stents (mostly self-expanding). Over a mean fol-
low-up of 16 months, primary patency rates of 27% and 9% 
at 1 and 2 years, and secondary patency rates of 71% and 39%, 
respectively, were reported. In another recent series by Haage 
et al.
22) 50 patients who underwent stent placement as the pri-
mary treatment for central venous obstruction were evaluat-
ed. They reported primary patency rates of 56% and 28% at 
1 and 2 years, respectively. Disadvantages of stent placement 
include potential collateral vein obstruction, shortening and 
migration of the stent, infection, and the loss of outflow in the 
extremity if the stent should fail.
23)24)
In a retrospective comparison of surgical and percutane-
ous treatment for graft thrombosis, Sands et al.
25) performed 
75 surgical thrombectomies and 71 percutaneous pharma-
comechanical procedures and observed no significant dif-
ferences in success rates, primary patencies, and rate of com-
plications.
Although PTA and surgery have comparable initial success 
rates, recurrence is invariably more frequent after the former.
26)27) 
The treating physician must be prepared for repeat interven-
tions, sometimes multiple, over the months and years after 
the initial declotting procedure. According to Haage,
28) 48 epi-
sodes of re-stenosis and 27 episodes of re-occlusion were not-
ed in 54 hemodialysis patients, amounting to an average of 1.4 
re-interventions per patient in a mean follow-up period of 13 
months.
Complications of angioplasty have been reported in about 
2-16% of cases, with the most common being immediate ve-
nous rupture during the procedure, the formation of pseu-
doaneurysms, acute thrombosis and periprocedural bacte-
remia.
5)6) Reaction to the contrast has not implicated a higher 
mortality rate of these patients.
5)6) 
The current study was conducted in a relatively small num-
ber of patients. Therefore, further randomized, large-scale 
studies are required.
In conclusion, PTA is an effective therapy in restoring the 
function of failing AVFs.Woo Shin Kim, et al.   517
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